Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: A1C is associated with diabetes complications but does not reflect glycemic variability (GV), which may worsen outcomes by inducing inflammation, oxidative stress, and cardiac arrhythmias. We tested whether a glucagon-like peptide 1 agonist-based regimen can reduce GV and cardiometabolic risk markers while maintaining similar A1C levels in people with insulin-requiring type 2 diabetes and high cardiovascular risk. RESEARCH DESIGN AND METHODS: After run-in on metformin and basal-bolus insulin (BBI), 102 participants continued metformin and basal insulin and were randomized to exenatide dosing before the two largest meals (glucacon-like peptide-1 receptor agonist and insulin [GLIPULIN group]) or continuation of rapid-acting insulin analogs (BBI group). Indices of GV by continuous glucose monitoring (CGM), hypoglycemia, weight, risk markers, and cardiac arrhythmias were assessed. The primary end point was change in glucose coefficients of variation (CV) by CGM from baseline to 26 weeks. RESULTS: At randomization, the median A1C was 7.3% (57 mmol/mol) for GLIPULIN and 7.4% (56.3 mmol/mol) for BBI, and glucose CVs were 30.3 for BBI and 31.9 for GLIPULIN. At 26 weeks, A1C levels were similar (7.1% [54 mmol/mol] vs. 7.2% [55 mmol/mol]), whereas mean CV improved with GLIPULIN (−2.4 vs. 0.4, P = 0.047). Other GV indices followed similar nonsignificant patterns of improvement with GLIPULIN. There were no differences in hypoglycemic events during CGM or arrhythmias during electrocardiographic monitoring. On-trial changes in body weight (−4.8 kg vs. +0.7 kg, P < 0.001), alanine aminotransferase (P = 0.0002), and serum amyloid A (P = 0.023) favored GLIPULIN. CONCLUSIONS: GLIPULIN reduced GV, weight, and some cardiometabolic risk markers while maintaining equivalent A1C levels versus BBI and might improve clinical outcomes in a larger trial.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Limited data support the possibility that GV is involved in the pathogenesis of vascular complications of diabetes by inducing inflammatory activation and oxidative stress (52,53).”
From Targets for Glycemic Control (2018) · cites this paper as [52]
In the citing paper
“Despite the improvement in GV, there was no statistically significant difference in cardiac arrhythmias”
From Glycemic variability and cardiovascular disease in patients with type 2 diabetes (2021) · cites this paper as [54]
In the citing paper
“They reported that GLP1-RA resulted in significant reductions in GV determined by CGM compared with prandial insulin.”
From Glycemic variability and cardiovascular disease in patients with type 2 diabetes (2021) · cites this paper as [54]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 2×
“26 weeks 45 3,967 (4,197) 1,625 (5,642) 43 2,583 (3,011) 1,113 (3,129) 0.”
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality
Orchard, T. J., Nathan, D. M., Zinman, B., Cleary, P., Brillon, D., Backlund, J.-Y. C., & Lachin, J. M. (2015) · JAMA · doi:10.1001/jama.2014.16107 · Cited by 437
Chow, E., Bernjak, A., Williams, S., Fawdry, R. A., Hibbert, S., Freeman, J., Sheridan, P. J., & Heller, S. R. (2014) · Diabetes · doi:10.2337/db13-0468 · Cited by 403 · cited 1×
“Furthermore, hypoglycemia is strongly associated with GV and may promote cardiac arrhythmias (10) while limiting the ability of insulin therapy to attain desired levels of control of A1C.”
BackgroundGlycemic Variability and Diabetes Complications: Does It Matter? Of Course It Does!
Hirsch, I. B. (2015) · Diabetes Care · doi:10.2337/dc14-2898 · Cited by 282
Diamant, M., Nauck, M. A., Shaginian, R., Malone, J. K., Cleall, S., Reaney, M., de Vries, D., Hoogwerf, B. J., MacConell, L., Wolffenbuttel, B. H. R., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0876 · Cited by 228
Proinflammatory cytokines in response to insulin-induced hypoglycemic stress in healthy subjects
Razavi Nematollahi, L., Kitabchi, A. E., Stentz, F. B., Wan, J. Y., Larijani, B. A., Tehrani, M. M., Gozashti, M. H., Omidfar, K., & Taheri, E. (2009) · Metabolism · doi:10.1016/j.metabol.2008.10.018 · Cited by 210
Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes
Cervera, A., Wajcberg, E., Sriwijitkamol, A., Fernandez, M., Zuo, P., Triplitt, C., Musi, N., DeFronzo, R. A., & Cersosimo, E. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00030.2008 · Cited by 157
Ratner, R. E., Rosenstock, J., Boka, G., & on behalf of the DRI6012 Study Investigators (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03020.x · Cited by 155
Poon, T., Nelson, P., Shen, L., Mihm, M., Taylor, K., Fineman, M., & Kim, D. (2005) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2005.7.467 · Cited by 106
Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists
Uccellatore, A., Genovese, S., Dicembrini, I., Mannucci, E., & Ceriello, A. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0127-x · Cited by 99
The Challenges of Measuring Glycemic Variability
Rodbard, D. (2012) · Journal of Diabetes Science and Technology · doi:10.1177/193229681200600328 · Cited by 84
The FLAT-SUGAR Trial Investigators (2015) · Diabetes Care · doi:10.2337/dc14-2689 · Cited by 39
Self-citationFeasibility of 10-Day Use of a Continuous Glucose-Monitoring System in Adults With Type 1 Diabetes
Garg, S. K., Voelmle, M. K., & Gottlieb, P. A. (2008) · Diabetes Care · doi:10.2337/dc08-1745 · Cited by 18
Cited by
The Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665
Glycaemic variability in diabetes: clinical and therapeutic implications
Ceriello, A., Monnier, L., & Owens, D. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30136-0 · Cited by 588
Continuous glucose monitoring: a review of recent studies demonstrating improved glycemic outcomes
Rodbard, D. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0035 · Cited by 458
Toward Defining the Threshold Between Low and High Glucose Variability in Diabetes
Monnier, L., Colette, C., Wojtusciszyn, A., Dejager, S., Renard, E., Molinari, N., & Owens, D. R. (2017) · Diabetes Care · doi:10.2337/dc16-1769 · Cited by 390
“diabetes treated with insulin, the means of %CV were approximately the same as the values observed at baseline in the population of the FLAT-SUGAR trial (10,29) using a newer generation of”
MethodResultContinuous glucose monitoring: A review of the technology and clinical use
Klonoff, D. C., Ahn, D., & Drincic, A. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.08.005 · Cited by 320
Metadata
- Authors
- The FLAT-SUGAR Trial Investigators
- Corresponding author
- The FLAT-SUGAR Trial Investigators
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-04-19
- Volume
- 39
- Issue
- 6
- Pages
- 973-981
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2403039904
- Cited by
- 135
- References
- 21
- Citations by year
- 2026: 8 · 2025: 9 · 2024: 4 · 2023: 5 · 2022: 5 · 2021: 17 · 2020: 11 · 2019: 20 · 2018: 23 · 2017: 20 · 2016: 13
- FWCI
- 25.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Sanofi
- Bristol-Myers Squibb
- AstraZeneca
- Bayer
- Becton Dickenson
- Dexcom
- Medicomp
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- glycemic variability, type 2 diabetes, GLP-1 receptor agonists, exenatide, rapid-acting insulin analogs, multiple daily insulin injections, cardiovascular risk, glycemic control, HbA1c, hypoglycemia, cardiac arrhythmias, body weight, cardiometabolic risk markers, serum amyloid A, alanine aminotransferase
- MeSH terms
- Exenatide, Adult, Aged, Alanine Transaminase, Serum Amyloid A Protein, Arrhythmias, Cardiac, Blood Glucose, Body Weight, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Metformin, Middle Aged, Peptides, Risk Factors, Venoms, Insulin, Short-Acting, Meals
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.